---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-316928"
form_type: "8-K"
ticker: "SPRB"
cik: "0001683553"
company_name: "SPRUCE BIOSCIENCES, INC."
filed_at: "2026-07-27T12:05:15+00:00"
generated_at: "2026-07-27T12:10:11.720105+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Spruce Biosciences appoints Adrian Quartel as Chief Medical Officer

## Summary
- Dr. Quartel replaces Dr. Kirk Ways, who had been serving as Interim CMO; Dr. Ways remains on the Board.
- Quartel brings 25+ years pharma experience, most recently CMO of Zevra Therapeutics.
- He previously led global medical affairs at BioMarin, launching six rare-disease treatments.
- Quartel holds an M.D. from Erasmus University and is board certified in pharmaceutical medicine.

## SEC filing metadata
- accession: 0001193125-26-316928
- form_type: 8-K
- ticker: SPRB
- cik: 0001683553
- company_name: SPRUCE BIOSCIENCES, INC.
- filed_at: 2026-07-27T12:05:15+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1683553/000119312526316928/0001193125-26-316928-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1683553/000119312526316928/sprb-20260727.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-316928
- JSON: https://secwatch.observer/filing/0001193125-26-316928.json
- Plain text: https://secwatch.observer/filing/0001193125-26-316928.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.